Comparative pharmacokinetics of orbifloxacin following a single intravenous or oral administration to healthy and diabetic rats

Scandinavian Journal of Laboratory Animal Science

Volumn 38, Issue 2, 2011, Pages 99-107

  Gebru, Elias ^a   Chang, Zhi Qiang ^a   Cheng, Henrique ^b   Lee, Joong Su ^a   Kim, Jong Choon ^c   Park, Seung Chun ^a  

^a Kyungpook National University   (South Korea)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ORBIFLOXACIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; DIABETES MELLITUS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG SAFETY; FLUORESCENCE IMAGING; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; RAT; SENSITIVITY AND SPECIFICITY; SINGLE DRUG DOSE;

RATTUS;

EID: 84865663039     PISSN: 09013393     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Bae, SK, JY Kim, SH Yang, JW Kim, T Kim and MG Lee. Pharmacokinetics of oltipraz in rat models of diabetes mellitus induced by alloxan or streptozotocin. Life Sci. 2006, 78(20): 2287-94.
2. Boxenbaum, H. Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab Rev. 1984. 15 (5-6): 1071-121
3. Carpenter, JW. Exotic Animal Formulary. 3rd ed. Elsevier Saunders, St. Louis, MO. 2005.
4. Davis, JL, MG Papich and A Weingarten. The pharmacokinetics of orbifloxacin in the horse following oral and intravenous administration. J Vet Pharmacol Ther. 2006, 29,191-7.
5. Elias, G., JS Lee, MH Hwang, YS Park, KH Cho, YH Kim and SC Park. Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Integration of Orbifloxacin in Korean Hanwoo Cattle. J Vet Pharmacol Ther. doi: 10.1111/j.1365-2885.2008.01027.x.
6. Elias, G, JS Lee, ZQ Chang, MH Hwang, H Cheng, and SC Park. Integration of Pharmacokinetic and Pharmacodynamic Indices of Orbifloxacin in Beagle Dogs after a Single Intravenous and Intramuscular Administration. Antimicrob Agents Chemother, 2009.In Press.
7. Emily, H. Rodent Dermatology. J Exot Pet Med. 2007, 16(4), 238-255
8. Engberg, J, FM Aarestrup, E Taylor, P Gerner-Smidt and I Nachamkin. Quinolone and macrolide resistance in Campylobacter jejuni and C. coli: resistance mechanisms and trends in human isolates. Emerg Infect Dis. 2001, 7, 24-34.
9. Flecknell, P. Developments in the veterinary care of rabbits and rodents. In Practice. 1998, 20, 286-295
10. Ganière, JP, C Mèdaille and F Etorè. In vitro antimicrobial activity of orbifloxacin against Sta- phylococcus intermedius isolates from canine skin and ear infections. Res Vet Sci. 2004, 77, 67-71
11. Goudah, A and K Abo-El-Sooud. Pharmacokinetics and milk penetration of orbifloxacin after intravenous and intramuscular injections to dromedary lactating camels (Camelus dromedaries). J Vet Pharmacol Ther. 2008, 31, 276-280.
12. Goudah, A, HJ Cho, HC Shin, JH Shim, NL Regmi, M Shimoda and AM Abd El-Aty. Pharmacokinetics and milk distribution characteristics of orbifloxacin following intravenous and intramuscular injection in lactating ewes. J Vet Pharmacol Therap. doi: 10.1111/j.1365-2885.2008.01046.x.
13. Grosset, NE. Pharmacokinetic and pharmacodynamic issues in the treatment of bacterial infectious diseases. Eur J Clin Microbiol. 2004, 23, 271-88.
14. Gwilt, PR, RR Nahhas and WG Tracewell. The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet.1991, 20 (6), 477-90
15. Heinen, E. Comparative serum pharmacokinetics of the fluoroquinolones enrofloxacin, difloxacin, marbofloxacin, and orbifloxacin in dogs after single oral administration. J Vet Pharmacol Ther. 2002, 25, 1-5.
16. Iherke, PJ, MG Papich and TC Demanuelle. The use of fluoroquinolones in veterinary dermatology. Vet Dermatol. 1999, 10,193-204
17. Lee, DY, MG Lee, HS Shin and I Lee. Changes in omeprazol pharmacokinetics in rats with diabetes induced by alloxan or streptozotocin: faster clearance of omeprazol due to induction of hepatic CYP1A2 and 3A1. J Pharm Pharmaceut Sci. 2007, 10 (4),420-433.
18. Marin, P, E Escudero, E Fernandez-Varon and CM Carceles. Pharmacokinetics and milk penetration of orbifloxacin after intravenous, subcutaneous, and intramuscular administration to lactating goats. J Dairy Sci. 2007, 90(42),19-25.
19. Marin, P, E Fernandez-Varon, E Escudero and CM Carceles. Pharmacokinetic-pharmacodynamic integration of orbifloxacin in rabbits after intravenous, subcutaneous and intramuscular administration. J Vet Pharmacol Ther. 2007. 31, 77-82.
20. Matsumoto, S, M Nakai, M Yoshida and H Katae. A study of metabolites isolated from urine samples of pigs and calves administered orbifloxacin. J Vet Pharmacol Ther.1999, 22, 286-9.
21. Matsumoto, S, M Nakai, M Yoshida and H Katae. Absorption, distribution and excretion of orbifloxacin in swine and calves. J Japan Vet Med Ass. 1998, 51, 13-18 (In Japanese with English abstract)
22. Matsumoto, S, M Takahashi, N Kitadai and H Katae. A study of metabolites isolated from the urine samples of cats and dogs administered orbifloxacin. J Vet Med Sci. 1998, 60, 1259-61.
23. Mckellar, QA, SF Sanchez Bruni and DG Jones. Pharmacokinetic/pharmacodynamic relationships of antimicrobial drugs used in veterinary medicine. J Vet Pharmacol Ther. 2004, 27, 503-514.
24. Michelle, W. Pet rodents: What every vet should know. Irish Vet J. 2008, 61(3), 176-181.
25. Mitchell, MA. Enrofloxacin. J Exot Pet Med, 2006, 15(1), 66-69.
26. Morris, TH. Antibiotic therapeutics in laboratory animals. Lab Anim, 1995, 29, 16-36
27. Nakamura, S. Veterinary use of new quinolones in Japan. Drugs, 49 Suppl 2. 1995, 152-8.
28. O'Connor, P, J Feely. Clinical pharmacokinetics and endocrine disorders. Therapeutic implications. Clin Pharmacokinet. 1987, 13(6), 345-64
29. Papich, MG and JE Riviere. Fluoroquinolone antimicrobial drugs. In: Adams, HR (ed.). Veterinary Pharmacology and Therapeutics, 8th ed. Iowa State Press, Ames Iowa. 2001, 898-917.
30. Papich, MG. Drug Therapy and Selection in Exotic Medicine. Supplementary Compendium on Continuing Education for the Practicing Veterinarian. 2003, 25(3), 15-20.
31. Ramirez, HE. Antimicrobial drug use in rodents, rabbits and ferrets. In: Giguère, S, JF Prescott, JD Baggot, RD Walker, PM Dowling (Eds.). Antimicrobial therapy in veterinary medicine. 4th ed, Blackwell publishing, Ames Iowa. 2007,565-581.
32. Rand, JS, LM Fleeman, HA Farrow, DJ Appleton, and R Ledere. Canine and Feline Diabetes Mellitus: Nature or Nurture? 2006. http://www.uq.edu. au/ccah/index.html?page=43 608 &pid=0.
33. Szkudelski, T The mechanism of alloxan and streptozotocin action in β- cells of the rat pancreas. Physiol Res. 2001. 50, 536-546.
34. Vallurupalli, S, G Huesmann, J Gregory and MG, Jakoby. Levofloxacin-associated hypoglycaemia complicated by pontine myelinolysis and quadriplegia. Diabet Med. 2008, 25, 856-859.